Rocket Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-69.6M | $-62.1M | $-59.7M | $-61.9M | $-65.7M | $-58.3M | $-66.7M | $-57.8M |
| Depreciation & Amortization | $1.8M | $1.7M | $1.4M | $1.2M | $1.2M | $1.1M | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $11.3M | $10.3M | $9.9M | $10.3M | $10.2M | $8.9M | $9.7M | $7.7M |
| Net Cash from Operating Activities | $-53.8M | $-56.9M | $-29.3M | $-57.1M | $-50.9M | $-57.6M | $-56.0M | $-43.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.9M | $2.0M | $4.6M | $4.7M | $4.1M | $3.0M | $3.0M | $503.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $55.6M | $35.0M | $-140.8M | $48.3M | $31.2M | $-36.7M | $-108.6M | $23.5M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $1.5M | $1.2M | $391.0K | $189.5M | $182.0K | $18.3M | $108.4M | $29.5M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-55.8M | $-58.9M | $-34.0M | $-61.8M | $-55.0M | $-60.6M | $-59.0M | $-44.4M |